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Abstract
The treatment and management of COPD by inhalation to the lungs has emerged as an attractive 
alternative route to oral dosing due to higher concentrations of the drug being administered to site 
of action. In this study, Nanocomposite Microparticles (NCMPs) of microRNA (miR-146a) 
containing PGA-co-PDL nanoparticles (NPs) for dry powder inhalation were formulated using L-
leucine and mannitol. The spray-drying (Buchi B290) process was optimised and used to 
incorporate NPs into NCMPs using mix of L-leucine and mannitol excipients in different ratios (F1; 
100:0% w/w, F2; 75:25% w/w, F3; 50:50% w/w, F4; 25:75% w/w, F5; 0:100% w/w) to investigate 
yield %, moisture content, aerosolisation performance and miR-146a biological activity. The 
optimum condition was performed at feed rate 0.5 ml/min, aspirator rate 28 m3/h, atomizing air 
flow rate 480 L/h, and inlet drying temperature 70 °C which produced highest yield percentage and 
closest recovered NPs size to original prior spray-drying. The optimum formulation (F4) had a high 
yield (86.0 ± 15.01%), recovered NPs size after spray-drying 409.7 ± 10.05 nm (initial NPs size 
244.8 ± 4.40 nm) and low moisture content (2.02 ± 0.03%). The aerosolisation performance showed 
high Fine Particle Fraction (FPF) 51.33 ± 2.9%, Emitted Dose (ED) of 81.81 ± 3.0%, and the mass 
median aerodynamic diameter (MMAD) was ≤5 µm suggesting a deposition in the respirable region 
of the lungs. The biological activity of miR-146a was preserved after spray-drying process and 
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miR-146a loaded NCMPs produced target genes IRAK1 and TRAF6 silencing. These results 
indicate the optimal process parameters for the preparation of NCMPs of miR-146a-containing 
PGA-co-PDL NPs suitable for inhalation in the treatment and management of COPD.
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1 Introduction
Chronic obstruction pulmonary disease (COPD) is a heterogeneous inflammatory disease characterised by 
airflow limitation, narrowing of the small airways and destruction of alveoli walls, which is considered a 
hallmark of emphysema (Cosio et al., 2009). An additional feature is chronic bronchitis which is associated 
with mucus and inflammation of the airways (Cosio et al., 2009). The treatment of COPD by inhalation to the 
lungs has emerged as an attractive alternative route to oral dosing due to higher concentrations of the drug 
being administered to site of action, which avoids degradation, by the strong acids and enzymes associated 
with the gastrointestinal tract.
MicroRNA (miRNA)-based therapeutics have emerged as a tractable approach for clinical intervention in 
respiratory diseases (Ebrahimi and Sadroddiny, 2015; Fujita et al., 2013; Kishore et al., 2014). The ability of 
miR-146a to downregulate the interleukin 1 receptor (IL-1R) and Toll-like receptor (TLR) signalling 
components IL-1 receptor-associated kinase (IRAK1) and tumour necrosis factor (TNF) receptor-associated 
factor (TRAF6) supports negative feedback regulation of IL-1β, IL-6 and IL-8 (Taganov et al., 2006). 
However, the delivery of miRNA to site of action considers one of the main concerns of developments of 
miRNA therapeutics. The physicochemical properties, such as hydrophilicity and negative charge, make it 
difficult for these molecules to cross biological barriers (Yin et al., 2014).
During the last few years, there has been a growing interest in nanotechnology for pulmonary drug delivery. 
The nanoparticles (NPs) have the ability to interact with intracellular and extracellular components of cells 
loaded with therapeutic agents for systemic and local delivery to treat diseases (Borm et al., 2006; Labiris and 
Dolovich, 2003; Merchant et al., 2016; Osman et al., 2018; Papay et al., 2017; Petkar et al., 2018; Rodrigues et 
al., 2018; Saleem et al., 2017). Therefore, using NPs is an interesting delivery strategy for small nucleic acids 
to treat respiratory diseases. However, NPs in the dry powder form do not deposit efficiently in the deep lungs, 
due to their low inertia and size (Kunda et al., 2013; Sung et al., 2007). Furthermore, the ideal particle size for 
optimal particle deposition in the deep lung ranges between 1 and 5 µm in diameter (Sakagami, 2006). 
Therefore, NPs can be incorporated into dry powder microparticles (NCMPs) of aerodynamic particle size 1–
5 µm through spray-drying (Alfagih et al., 2015; Kunda et al., 2015a).
Spray-drying is a one step process that converts liquid emulsion solution or suspension to dry powder, and is 
controlled by different parameters to provide desirable physical characteristics of powders and aerosolisation 
properties, including the morphology, moisture content, particle size and density (Sakagami, 2006; Saleem et 
al., 2017; Ungaro et al., 2012). Moreover, excipients such as sugars and amino acids can be added to the spray 
dried liquid formulation to enhance aerosolisation properties powders (Bosquillon et al., 2001; Tawfeek et al., 
2013). The selection of appropriate excipients for inhalation leads to optimal and functional dry powder 
formulation and can help preserve NPs and nucleic acid integrity. If NPs aggregate and become very large i.e 
500 nm, this can impact on diffusing through lung lining fluid and uptake by cells hence reducing miRNA 
uptake into cells (Alfagih et al., 2015).
L- Leucine is one of the amino acids that has been used as a dispersing agent that improves aerosolisation
properties for dry powders, reduces contact cohesion between the particles and prevents aggregation (Tawfeek
et al., 2011). Sugar excipients such as mannitol are commonly used in spray-drying with good safety
characteristics, are less hygroscopic than lactose and they have European approval for dry powder inhalation (
Burness and Keating, 2012; Jensen et al., 2010; Pilcer and Amighi, 2010).
Similarly, these excipients can protect, and stabilize the NPs and encapsulated materials during spray-drying 
process including operational high temperature and mechanical stress (Alfagih et al., 2015; Kunda et al., 
2015a,b; Rodrigues et al., 2018; Tawfeek et al., 2011). In addition, excipients added to the spray-dried 
formulations induce the production of a desirable aerodynamic particle size 1–5 µm and release of the active 
ingredients after they disperse in the lung lining fluid (Jensen et al., 2010; Saluja et al., 2010). Taking into 
account the advantage of the promising biological effects of inhaled siRNA in the lung, there have been 
limited work exploring dry powder inhalation of miRNA via spray-drying. In this study, L-leucine and 
mannitol were mixed together as dispersion enhancer and protective excipients. To our knowledge this is the 
first time that miRNA was formulated into inhalable dry powder NCMPs using a mix of amino acid and sugar 
excipient. We optimised the production of NCMPs of miR-146a-containing PGA-co-PDL NPs for dry powder 
inhalation in terms of size, morphology, aerosol performance, moisture content and miRNA functionality.
2 Materials and methods
2.1 Reagents
Novozyme 435 (a lipase from Candida antartica immobilized on a microporous acrylic resin) was purchased 
from Biocatalytics, USA and DOTAP was purchased from Avanti Polar lipids, Alabaster, AL, USA. Solvents 
were purchased from Fischer chemicals (Fischer Scientific, UK). Poly (vinyl alcohol) PVA, Mw of 13–23 kDa 
87–89% hydrolysed, RPMI-1640 medium with L-glutamine, L-leucine, D-Mannitol and RNase-free diethyl 
pyrocarbonate (DEPC) water were purchased from Sigma Aldrich, UK. Human adenocarcinomic alveolar 
basal epithelial cell line, A549, was purchased from ATCC. A synthetic miR-146a mimic with a FAM-label on 
the sense 5′ FAM-CCGGGCAAUUCAGUUUCUACA-dTdT-3′, was purchased from Eurogenetec, UK with 
the sequence: sense 5′ FAM-CCGGGCAAUUCAGUUUCUACA-dTdT-3′, antisense 5′ dTdT-
GGCCCGUUAAGUCAAAGAUGU-3′.
2.2 Nanoparticle preparation and miRNA adsorption
PGA-co-PDL NPs were prepared using an oil in water (o/w) single emulsion method, as previously described (
Kunda et al., 2014) with modification. DOTAP 15% w/w was added to the organic phase to prepare cationic 
NPs. The miR-146a mimic was added to 1 ml solution of RNase free water containing NPs (to obtain a final 
NP:miRNA weight ratio of 250:1) and mixed using a HulaMixer Sample Mixer (Life Technologies, UK) at 
20 rpm and 25 °C at 2 h. After adsorption, RNase free water was added to a total volume of 4 ml prior to 
separation of free miR-146a from the adsorbed miR-146a by ultracentrifugation at 35000 × g, for 40 min at 
4 °C using an Optima L-80 Ultracentrifuge (Beckman, UK).
2.3 Particle size and miRNA adsorption characterisation
The mean particle size and polydispersity index (PDI) of the NPs were analysed by dynamic laser scattering 
using a Zetasizer Nano ZS, Malvern Instruments Ltd, UK. The NPs (10 mg) were diluted with 4 ml distilled 
water and 1 ml of the diluted sample was placed into a measuring cuvette. The concentration of adsorbed miR-
146a was determined indirectly from the difference in miR-146a concentration before and after loading by UV 
absorbance at 260 nm using a NanoDrop 2000C (Thermo Fisher Scientific, and USA).
2.4 Preparation of Nanocomposite Microparticles
The Nanocomposite Microparticles (NCMPs) were prepared by spray-drying the NPs suspension from 
different aqueous solutions containing L-leucine and mannitol in various ratios (F1; 100:0% w/w, F2; 75:25% 
w/w, F3; 50:50% w/w, F4; 25:75% w/w, F5; 0:100% w/w), with a NPs to L-leucine and mannitol (NCMPs) 
ratio of 1:1.5 w/w (Alfagih et al., 2015) using a Büchi B- 290 mini spray-dryer (Büchi Labortechnik, Flawil, 
Switzerland) containing a standard two-fluid nozzle (0.7 mm diameter) applying the following spray-drying 
conditions; feed rate 0.5 ml/min, aspirator rate 28 m3/h, atomizing air flow rate 480 L/h, inlet drying 
temperature 70 °C (corresponding outlet temperature of approximately 47 ˚C). Dry particles were separated 
from the airstream using a high-performance cyclone (Büchi Labortechnik), collected and stored in desiccator 
at room temperature until further use.
2.5 Characterisation of Nanocomposite Microparticles
2.5.1 Yield, Morphology, particle size and moisture content
The dry powder yield was determined as the percentage mass of expected powder (n = 3) according to 
following equation (Eq. (1)):
The spray-dried powder was examined using a scanning electron microscope (SEM), Quanta 450, FEI, 
Oregon, USA). The spray-dried samples were mounted on an aluminium stub with adhesive, coated with gold 
(40–60 nm) and then observed at high vacuum. The NPs recovery from NCMPs (2 mg) was determined by re-
dispersing in 4 ml water and vortexed for 20 s at 100 rpm to release the recovered NPs, 1 ml of the diluted 
sample was loaded into a measuring cuvette, and the measurements were recorded at 25 °C. The mean particle 
size and polydispersity index (PDI) of the NPs were analysed by dynamic laser scattering using a Zetasizer 
Nano ZS, Malvern Instruments Ltd, UK. The water content of the NCMPs powder was determined by 
thermogravimetric analysis (TGA), using a Linseis STA PT 1750 Model Thermo Anaylzer system, Germany. 
(1)
NCMPs powder (10 mg) was heated between 25 and 650 °C at constant rate 10 °C/min in nitrogen gas. The 
weight loss (%) due to water evaporation, was recorded between 25 and 120 °C.
2.5.2 Powder density and aerodynamic diameter
The Tapped density of the NCMPs was determined by adding approximately 0.2 g of powder to a 5 ml 
measuring cylinder (Alfagih et al., 2015). The initial bulk volume (Vo) was recorded and then again following 
mechanical tapping ten times (V10), then five hundred times (V500), then after one thousand and two hundred 
fifty (V1250) taps until no reduction in the particle volume was noticed. The theoretical aerodynamic diameter 
( ) was determined based on the data obtained from geometric particle size ( ) and tapped density ( ) 
according to Eq. (2).  is the unit density (1 g/cm3)
2.5.3 In vitro aerosolisation studies
The aerosol performance of the NCMPs was evaluated using a next generation impactor (NGI). The spray-
dried powder (10 mg) was manually loaded into four hydroxypropyl methylcellulose HPMC size 3 capsules 
(Qualicaps, Japan). The capsules were pierced using a 2-pin Cyclohaler® (Teva pharma) and aerosolised into 
the NGI that was connected to a pump (Copley Scientific, UK). The airflow was measured and adjusted prior 
to experiment using a flow meter (Copley Scientific, UK). The flow rate was operated at 60 L/min for 4 s. The 
plates were coated with polyethylene glycerol (PEG-200) to decrease powder bounce ( Edwards et al., 1998 ). 
The amount of particles deposited in each stage of the impactor was evaluated gravimetrically by measuring 
the difference in mass before and after powder deposition ( Meenach et al., 2013a; Meenach et al., 2013b ). The 
fine particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF), and emitted dose (ED) were 





The FPD is defined as the mass of the drug deposited in the NGI with dae ≤ 4.46 μm, FPF % is the fraction of 
emitted dose deposited in the NGI with dae < 4.46 μm, RF % is the mass of powder ≤4.46 μm and ED is the 
amount of powder exiting the inhaler. The mass mean aerodynamic diameter (MMAD, µm) and geometric 
standard deviation (GSD, µm) were calculated from log probability analysis 
(http://www.mmadcalculator.com/).
2.6 Semi-quantitative reverse transcriptase PCR
A549 cells (3.8 × 105 cells per well) were seeded on a 6 well plate. After 24 h growth, the cells were incubated 
in serum free medium with miR-146a-NCMPs for 1 h. The miR-146a- NCMPs mixture was then replaced with 
complete medium and the cells incubated for 24 h. Total RNA was extracted using the RNeasy Mini kit 
according to the manufacturer’s instructions. Reverse transcription for cDNA generation was performed on 
200 ng RNA using miScript reagents (Qiagen, Manchester, UK). Levels of IRAK1 transcripts, were assessed 
using RT2 qPCR Primer Assays in 20 µl reactions composed of 10 µl SYBR Green PCR master mix, 2 µl 
primers, 2 µl diluted cDNA and water to 20 µl. The reactions were amplified for three-step method. Expression 
was normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the 2−ΔΔ C t method ( Livak 
and Schmittgen, 2001 ), SYBR Green PCR reagents and PCR primers were purchased from Qiagen 
(Manchester, UK).
2.7 Statistical analysis
All statistical analysis were performed using Minitab® 16 Statistical Software. One-way analysis of variance 
(ANOVA) with the Tukey’s comparison was employed for comparing the formulations with each other. 
Statistically significant differences were assumed when p < 0.05. All values were expressed as the 
mean ± standard deviation.
3 Results and discussion
3.1 Spray-drying optimization, moisture content, recovered particle size and yield
The spray-drying optimisation process was utilised to incorporate NPs into NCMPs using different ratios of L-
leucine and mannitol excipients. Spray-drying parameters used showed, that outlet temperature 47 °C was 
below melting point of PGA-co-PDL NPs ( Tawfeek et al., 2011, 2017 ). Monitoring and maintaining a low 
outlet temperature can reduce agglomeration, and reduced the risk of small nucleic acid denaturation ( Mohajel 
et al., 2012 ).
Water content for formulations (F1–F5) were within the range of moisture content (2.02 ± 0.03%–5.1 ± 0.37%) 
of spray-dried particles intended for lung deposition as reported by others ( Chew et al., 2005a; Ståhl et al., 
2002 ), ( Table 1 ). However, F4 (the optimum ratio of L-leucine to mannitol F4; 25:75% w/w) had the lowest 
moisture content, due to a higher percentage of mannitol ( Jensen et al., 2012 ), there was a time to the particles 
(6)
to be in spray drying chambers hence particles dry and reduced cohesion between particles resulting in 
increased powder respirability (Fig. 1) (Chew and Chan, 2002). Mannitol has hygroscopic properties enabling 
the formation of hydrogen bonds with water molecules causing water replacement, which stabilises the 
formulation (Chow et al., 2017; Clegg et al., 1982; Li et al., 2016; Sarmento et al., 2006; Schüle et al., 2008). 
A study by Rohani et al. demonstrated that mannitol used in a combination with amino acid (L-alanine), found 
that the formulation containing mannitol and amino acid had a moisture content range between 4 and 6% (
Rohani et al., 2014), which was similar to our results 2.02 ± 0.03–5.1 ± 0.37% (Table 1).
Table 1
Physical properties of spray-dried nanocomposite microparticles. Mean ± SD (n = 3).
Formulations Yield % NPs recovery size (nm) Tapped density (g/cm3) Water content (%)
F1 56.0 ± 11.30 958.3 ± 21 (−) 5.10 ± 0.37
F2 79.2 ± 10.10 1810.66 ± 18 0.17 ± 0.01 4.91 ± 0.20
F3 95.6 ± 2.80 3252.06 ± 26 0.13 ± 0.20 3.80 ± 0.90
F4 86.0 ± 15.01 409.7 ± 10.05 0.14 ± 0.01 2.02 ± 0.03
F5 84.0 ± 2.20 2174.6 ± 13 0.20 ± 0.05 3.77 ± 0.11
Note: The size of PGA-co-PDL miR-146a NPs prior to spray-drying was 244.80 ± 4.40 nm.
i The presentation of Tables and the formatting of text in the online proof do not match the final output, though
the data is the same. To preview the actual presentation, view the Proof.
Fig. 1
It was found that operational parameters such as feed rate, aspirator rate, atomised air flow, spray-drying inlet 
and outlet temperature had a significant impact on recovered particle size and yield of dry powders ( Alfagih et 
al., 2015 ). A similar observation was noted in spray-drying condition inlet 70 °C and outlet 47 °C temperature. 
It was found that the inlet temperature had affected (increased/decreased) the recovered NPs particle size and 
yield. This was due to a faster rate of drying resulting in decreased particle aggregation ( Mohajel et al., 2012 ) 
and residual moisture resulting in less particles sticking to the spray-drying chamber walls ( Billon et al., 2000 ). 
However, high inlet temperature may affect the small nucleic acids stability ( Mohajel et al., 2012 ).
When mannitol concentration was up to 50%, the yield varies from 56.0 ± 11.30% (F1) to 95.6 ± 2.80% (F3), 
whereas yield decreased to 86.0 ± 15.01 (F4) with 75% to 100% mannitol. Despite this variation in yield 
percentage, the NCMPs reported here have high yield values, which indicate the significant potential of using 
a mixture of mannitol and L-leucine. The values are much higher than the yield values reported in previous 
(A) The fine particle fraction (%) spray dried powder (B) mass mean aerodynamic diameter (µm) (C) Respirable fraction (%) (D)
Emitted dose (%) (E) Fine Particle Dose (µg). Data represent mean ± SD (n = 3), (*p < 0.05, ANOVA/Tukey’s).
studies from 40 to 50% (Alfagih et al., 2015; Kunda et al., 2015a; Tawfeek et al., 2011). Formulation F4 
produced the highest yield % of NCMPs 86.0 ± 15.01% (Table 1) (Jensen et al., 2010). Moreover, the increase 
of mannitol concentration lead to an increase in particle size from 244.80 ± 4.40 nm before spray-drying to 
409.7 ± 10.05 nm (Table 1) after spray-drying. F1-F3 showed large particle size recovery after spray drying 
ranges from 958.3 ± 21 to 3252.06 ± 26 nm, this large size particle was due to the mannitol crystallinity profile 
in the formulations and presence the different contents of mannitol and leucine in the formulations can affect 
the particle size (Pourshahab et al., 2011; Sou et al., 2011). As mentioned in the literature, low amount of 
mannitol or mannitol alone cause particle aggregation, therefore increase in particle size, whereas formulation 
containing more quantity of mannitol could prevent crystallisation of mannitol after spray drying (Lee et al., 
2011; Sou et al., 2011). However, F4 when re-dispersed, the NPs size returned to particle size before spray 
drying. Moreover, this particle size increase after spray-drying may be a result of particle cohesiveness due to 
Van der Waals force, capillary force, combination of leucine and mannitol and particles aggregation under 
operating conditions of spray-drying (Beck-Broichsitter et al., 2012; Chew and Chan, 1999; Chow et al., 2017; 
Sosnik and Seremeta, 2015). The high yield of F4 was associated with reduced loss of dry powder during the 
collection process which relies on centrifugal forces for collection of final dry powder due effective separation 
capacity of cyclone (Sosnik and Seremeta, 2015). Furthermore, the high yield was also associated with higher 
percentage of mannitol which has hygroscopic properties and stabilise the formulation as mentioned above due 
to the formation of hydrogen bonds with water molecules causing water replacement (Schüle et al., 2008). 
Hence, F4 was selected as the optimum formulation according to the high yield and lower moisture content 
and taken forward for target gene and protein expression, based on results of tapped density and aerosolisation 
data (Section 3.1 and 3.2).
3.2 In vitro aerosolisation studies
The in vitro aerosol dispersion properties of NCMPs were determined using NGI. The mass median 
aerodynamic diameters (MMAD) ranged from 4.20 ± 0.15 to 6.03 ± 1.08 µm. The NCMPs’ formulations (F1-
F4) showed that MMAD was less than ≤5 µm with F5 significantly greater at 6.03 ± 1.08 µm (p < 0.05, 
ANOVA/Tukey’s) (Fig. 1B). The corresponding GSD values between formulations were approximately 
similar in size from 1.75 ± 0.31–2.15 ± 0.53 µm. The difference suggests the spray-dried excipients influence 
MMAD, with F1-–F4 possessing less mannitol and more L-leucine than F5. A study by Jensen et al. showed 
that spray-dried NPs with high concentration mannitol resulted in larger MMAD size compared with spray-
dried NPs with lower mannitol concentration (Jensen et al., 2010). Another study by Chow et al. showed high 
amount of L-leucine with low amounts of mannitol led to the reduction of the MMAD size (Chow et al., 2017
). Despite the NCMPs’ formulations (F2-F4) containing different L-leucine and mannitol amounts, which 
affected and decreased MMAD values from 5.28 ± 0.71 µm (F4) to 4.93 ± 0.49 µm (F2) (Fig. 1B). Similar 
results were obtained by Chow et al. when various amounts of L-Leucine were used with mannitol in inhaled 
powder formulation, and they found the high amount of L-leucine in the formulation with low amount of 
mannitol led to reduction of the MMAD values (Chow et al., 2017). The amount of mannitol in F5 and 
absence of L-leucine may form aggregated powders which contributes to higher MMAD and a decrease in FPF 
(Fig. 1A) (Chow et al., 2017; Kaialy and Nokhodchi, 2013). This may be related to the surface activity of 
hydroxyl group of mannitol, which interacts with certain amine groups and effect the particle’s surface (
Bharate et al., 2016).
FPF % showed that F4 produced significantly higher FPF % (51.33 ± 2.90%) compared to the other 
formulations (p < 0.05, ANOVA/Tukey’s) (Lucas et al., 1999; Sou et al., 2013; Tawfeek et al., 2011). The ED 
values were all over 50% with highest value for F4 81.81 ± 3.0% (Fig. 1D). Adding L-leucine to spray-dried 
powders reduces the forces of attraction due to less contact points between particles forming rough particle 
surface and lower spray-dried powder aggregation, which causes greater dispersibility (Alfagih et al., 2015; 
Kunda et al., 2015a; Tawfeek et al., 2011). Furthermore, the L-leucine amount in the spray-dried powder had 
an effect on aerosolisation performance. A study by Sou et al. showed that L-leucine enhanced aerosolisation 
performance of mannitol formulations (Sou et al., 2011). The incorporation of L-leucine into F4 increased the 
FPF % and FPD. F4 had 25% L-leucine, which resulted in more than double FPF %, 51.33 ± 2.9% and FPD, 
20.53 ± 2.90 mg respectively compared to F5, 0% leucine with FPF %, 19.96 ± 1.2% and FPD 7.98 ± 1.20 mg (
Fig. 1A and E). Similar results were obtained by Chow et al. which found that the absence of L-leucine and 
high amount of mannitol in the formulation decreased FPF % (Chow et al., 2017). This difference was due to 
less powder stickiness and cohesiveness, as indicated in a study conducted by Gervelas et al. in which leucine 
was added to spray-dried powder (Gervelas et al., 2007).
The FPF, FPD, ED and MMAD values obtained from F4 would suggest very good aerosolisation properties 
and a deep lung deposition profile which is in agreement with other studies that used PGA-co-PDL NPs-
NCMPs (Kunda et al., 2015b). Hence, NCMPs when inhaled, L-leucine and mannitol will dissolve the lung 
lining fluid, subsequently releasing miR-146a-NPs to be taken up by lung cells and cause the required 
biological expression (Alfagih et al., 2015; Kunda et al., 2015b).
3.3 Morphology, powder density and aerodynamic diameter of formulation F4
The tapped density of PGA-co-PDL NCMPs F4 was 0.14 ± 0.01 g cm−3 (Table 1) and theoretical dynamic 
diameter (dae) was 0.63 ± 0.01 µm. The formulated NCMPs (F4) were analysed for morphology using SEM (
Fig. 2) and micrographs showed that NCMPs possessed a spherical shape and corrugated surface, which 
suggested this shape was due to the reduction in the cohesion between particles (Chew and Chan, 2001; Chew 
et al., 2005b). This occurred due to water evaporation that happened during the spray-drying process causing 
high vapour pressure. In addition, the presence of L-leucine in spray-dried particles, which has low density 
was capable of forming a shell that encapsulate the particles (Alfagih et al., 2015; Lucas et al., 1999; Sou et al., 
2013). These corrugated surface particles would have a larger surface area, leading to an increase in the 
particles’ capability to disperse in lung fluid thus releasing miR-146a-NPs. The aerosolisation properties with 
mannitol has been shown to be better than lactose, because of the corrugated spray-dried particles produced 
have less contact points and van der Waal forces, thus it is easier to disperse (Bharate et al., 2016; Vehring, 
2008). Furthermore, mannitol was also shown to be the best in formulation, a study by You et al. who 
investigated the use of spray-drying method by mixing mannitol and other sugars (trehalose, lactose and 
dextran) with amino acids (L-leucine, glycine and threonine), they found mannitol produce these corrugated 
particles with good aerosolisation behaviour (You et al., 2007).
The morphology of F4 particles that contains combination of L-leucine and mannitol appear to behave 
differently. As the corrugated particles formed, dries, causing detention and does not interfere with coating. It 
is therefore speculated that the presence of mannitol altered the core structure of the spherical drying particles. 
This combination of L-leucine and mannitol may also be advantageous in terms of aerosolisation efficacy, 
hence the FPF % is high. These results are consistent with a study by Sou et al. in which they used 
combination of mannitol and leucine, they found this combination produced corrugated particles with high 
aerosolisation ( Sou et al., 2011).
3.4 Effect of miR-146a-NCMPs on target gene and protein expression
To confirm miR-146a-NCMPs biological functionality after spray-drying, the expression of target genes 
IRAK1 and TRAF6 was assessed in A549 cells. Analysis of transcript levels showed that miR-146a expression 
against targeted genes IRAK1 and TRAF6 ( Fig. 3 ). The expression of IRAK1 and TRAF6 was normalised to 
GAPDH expression. The NCMPs results were comparable with the miR-146a-NPs. As shown in  Fig. 3 that 
miR-146a activity was maintained after spray-drying, indicating the ability of miR-146a-NCMPs. There were 
different apparent sensitivities of IRAK1 and TRAF6 to the miR-146a-NCMPs, where TRAF6 was 
significantly reduced with a relatively low dose due to miR-146a-binding sites in their 3′UTR. This suggests 
that the dry powder particles combining amino acid and sugar did not affect the miR-146a silencing activity 
despite aggregation of recovered NPs and protected biological activity of miR-146a.
Fig. 2
SEM images of F4 NCMPs, the scale bare represent 5 µm and 10 µm.
Fig. 3
Immunoblotting ( Fig. 4 ) supports that miR-146a activity was maintained after spray-drying, and reduced 
IRAK1 protein levels in A549 cells after 24 h and 48 h treatment. The β-actin was used as control. As shown in 
( Fig. 4 ), the protein level decreased in a dose-dependent manner compared to untreated cells. This suggested 
that IRAK1 protein levels were reduced in response to miR-146a-NCMPs. Despite nucleic acid being exposed 
to high temperatures of 47 °C during the drying process, and the use of the delivery formulation and excipients, 
the biological activity of miR-146a appears to have been preserved.
It appears that NCMPs delivered miR-146a-NPs to site of action, and produced the required gene knockdown 
by inhibiting IRAK1 and TRAF6 genes, which is in line with other studies that indicated miR-146a role in 
inhibiting expression of IRAK1 and TRAF6 genes ( Taganov et al., 2006 ). The local pulmonary delivery of 
miR-146a has played an important role by targeting multiple genes after inhalation with the dose spread over 
various parts in lung (Bhardwaj et al., 2009; He et al., 2005; Rossi, 2009 ). In fact, various studies have 
investigated siRNA and DNA delivery intended for inhalation ( Jensen et al., 2010; Liang et al., 2015, 2014 ), 
MiR-146a-NCMPs reduce miR-146a target expression. Levels of IRAK1 and TRAF6 were assessed by sqRT-PCR in A549 cells 
that had been exposed to miR-146a-NPs or miR-146a-NCMPs for 1 h washed then incubated for 24 h. The doses yielding the most 
consistent downregulation of the target genes are shown. Mean ± SD (n = 3).
Fig. 4
Western Blot expression of miR-146a reduced IRAK1 protein levels in A549 cells for 24 h and 48 h. Dark triangle represents 
lowest (left) to highest (right) miR-146a-NCMPs concentrations. Numbers under each band represent the densitometric readings 
relative to control samples that normalized each band to its corresponding β -actin control.
but limited research has been performed on miRNA pulmonary delivery. The miRNA-based therapy has 
showed interesting progress for treating different diseases, the MRX34 using miR-34 hepatocellular carcinoma 
and lung cancer have entered phase I clinical trials (Beg et al., 2017). In addition, miRagen using miR-29 to 
treat pulmonary fibrosis, through intravenous injection in vivo has reached the pre-clinical studies (
Montgomery et al., 2014). Although NPs size was larger than before spray-drying, activity of miR-146a was 
still retained and gene knockdown reduced. The final payload of miR-146a would range between 30 and 35 µg 
for in vivo and clinical studies. Therefore, the current study provides the feasibility of using miR-146a-
NCMPs for therapeutic purposes as pulmonary drug delivery that manages COPD rather than other 
medications.
4 Conclusion
The selected PGA-co-PDL NPs were incorporated into L-leucine and mannitol as a carrier to improve the 
powder’s aerosolisation properties. Five different formulations were prepared with various excipients ratios. 
The NPs’ size recovered after spray-drying (409.7 ± 10.05 nm) and geometric particle size is suitable for 
targeting the respiratory bronchiole. Although NPs size was larger than before spray-drying, activity of miR-
146a was still retained and gene knockdown reduced. Moreover, the optimum formulation had a high yield 
(86.0 ± 15.01%), and low moisture content (2.02 ± 0.03%) which is essential for powder aerosolization and 
formulation stability. The aerosolisation performance showed high FPF 51.33 ± 2.9%. The biological activity 
of miR-146a was preserved after spray-drying process and miR-146a loaded NCMPs produced gene silencing. 
The results indicated that the method has been optimised for the spray-drying of NCMPs with preserved miR-
146a activity demonstrating potential gene therapy administered via dry powder inhalation treatment of 
COPD.
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